A Phase II trial to evaluate the safety and efficacy of ATIR101 for the adjunctive treatment in hematopoietic stem cell transplantation (HSCT) pediatric patients with a hematologic malignancy, who are eligible for an HSCT but without the availability of a fully matched donor
Latest Information Update: 03 Apr 2017
At a glance
- Drugs T cell replacement therapy TH 9402 (Primary)
- Indications Graft-versus-host disease; Haematological malignancies
- Focus Therapeutic Use
- 03 Apr 2017 New trial record